Upadacitinib Reduces Extraintestinal Manifestations of UC: Study
Researchers evaluated phase 3 data comparing the oral JAK inhibitor with placebo for treating anemia, peripheral arthropathy, axial arthropathy, and other extraintestinal manifestations.
Medscape Medical News
source https://www.medscape.com/viewarticle/969264?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/969264?src=rss
Comments
Post a Comment